Fair Value Calculator Fair Value Calculator
EN DE

2170 (2170) Fair Value & Analysis

Healthcare · Market cap HK$383M

2 2170 2170 · HK
PriceHK$1.40
Fair ValueHK$0.6100
Upside-56.4%
Quality41/100
Watch 2170 for free — get notified when fair value or trend changes. Watch for free
Evidence: Low Range HK$0.4000 – HK$0.7600

Fair value as of: Jul 2, 2026

From 1 valuation models · updated today

Share price −3.4% over the past month.

Price vs Fair Value (12 months)

HK$4.15 HK$1.28 Fair Value HK$0.6100 Jun 2025 Jul 2026

12‑month range HK$1.28 – HK$4.15 · fair‑value band HK$0.4000 – HK$0.7600 · the HK$1.40 price screens above the HK$0.6100 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

2170 (2170) currently trades at HK$1.40, while our model-based Fair Value estimate is HK$0.6100 — implying the stock looks roughly 56.4% overvalued today. We read business quality at 41/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

Over the trailing twelve months, 2170 generated revenue of HK$233M at a net margin of -95.8%. Revenue declined 24.3% year over year. It earns a return on equity of -21.5%. The balance sheet holds a net cash position of HK$75.7M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$233M
Revenue growth (YoY) -24.3%
Net margin -95.8%
Return on equity -21.5%
Free cash flow −HK$243M FY2025
Operating margin -62.4%
More key figures
EPS (TTM) HK$-0.4400
Net cash HK$75.7M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

2170 reported revenue of HK$233M in FY2025 versus HK$107M in FY2021, a compound +21.4%/yr. Reported net income was −HK$223M in FY2025.

Revenue +21.4%/yr
FY21 HK$107M
FY22 HK$141M
FY23 HK$208M
FY24 HK$299M
FY25 HK$233M
Net income
FY21 −HK$144M
FY22 −HK$123M
FY23 −HK$192M
FY24 −HK$237M
FY25 −HK$223M

Is 2170 fairly valued? → Check now

Similar stocks

6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock Price Fair Value vs Fair Value
ABT ABT 1,600 MXN 1,228 MXN -23%
Abbott Laboratories, ABTT34 R$38.22 R$30.39 -20%
Stryker Corporation S1YK34 R$77.83 R$8.47 -89%
Medtronic plc MDT $80.25 $74.40 -7%
Boston Scientific Corporation B1SX34 R$248.75 R$221.81 -11%
Edwards Lifesciences Corporation EW $85.88 $41.02 -52%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is 2170 (2170) undervalued?
As of Jul 2, 2026, our model estimates a fair value of HK$0.6100 versus a price of HK$1.40 — about −56% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 2170?
Our model-based fair value for 2170 is HK$0.6100 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$1.40.
What is the quality score of 2170?
2170 has a Quality Score of 41/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of 2170 (2170)?
2170 reported trailing-twelve-month revenue of about HK$233M (latest available figure, as of Jul 2, 2026).
What is the net profit margin of 2170?
The net profit margin of 2170 is about -95.8%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.